JP2015214563A5 - - Google Patents

Info

Publication number

JP2015214563A5

JP2015214563A5 JP2015134473A JP2015134473A JP2015214563A5 JP 2015214563 A5 JP2015214563 A5 JP 2015214563A5 JP 2015134473 A JP2015134473 A JP 2015134473A JP 2015134473 A JP2015134473 A JP 2015134473A JP 2015214563 A5 JP2015214563 A5 JP 2015214563A5

Authority

JP

Japan

Prior art keywords

seq

variable region

light chain

chain variable

heavy chain

Prior art date

2015-07-03

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 102000025171 antigen binding proteins Human genes 0.000 claims description 42
• 108091000831 antigen binding proteins Proteins 0.000 claims description 42
• 239000000833 heterodimer Substances 0.000 claims description 36
• 210000004027 cell Anatomy 0.000 claims description 19
• 229920001184 polypeptide Polymers 0.000 claims description 17
• 102000004196 processed proteins & peptides Human genes 0.000 claims description 17
• 108090000765 processed proteins & peptides Proteins 0.000 claims description 17
• 102000039446 nucleic acids Human genes 0.000 claims description 13
• 108020004707 nucleic acids Proteins 0.000 claims description 13
• 150000007523 nucleic acids Chemical class 0.000 claims description 13
• 238000000034 method Methods 0.000 claims description 12
• 101710139349 Mucosal addressin cell adhesion molecule 1 Proteins 0.000 claims description 9
• 102100028793 Mucosal addressin cell adhesion molecule 1 Human genes 0.000 claims description 9
• 102000004169 proteins and genes Human genes 0.000 claims description 6
• 108090000623 proteins and genes Proteins 0.000 claims description 6
• 125000001433 C-terminal amino-acid group Chemical group 0.000 claims description 4
• 208000015943 Coeliac disease Diseases 0.000 claims description 4
• 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims description 4
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 4
• 230000021164 cell adhesion Effects 0.000 claims description 4
• 230000002401 inhibitory effect Effects 0.000 claims description 4
• 230000004481 post-translational protein modification Effects 0.000 claims description 4
• 230000000694 effects Effects 0.000 claims description 3
• 208000004396 mastitis Diseases 0.000 claims description 3
• 206010006458 Bronchitis chronic Diseases 0.000 claims description 2
• 206010009137 Chronic sinusitis Diseases 0.000 claims description 2
• 206010009900 Colitis ulcerative Diseases 0.000 claims description 2
• 208000011231 Crohn disease Diseases 0.000 claims description 2
• 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
• 206010033645 Pancreatitis Diseases 0.000 claims description 2
• 206010062164 Seronegative arthritis Diseases 0.000 claims description 2
• 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 2
• 201000006704 Ulcerative Colitis Diseases 0.000 claims description 2
• 230000003872 anastomosis Effects 0.000 claims description 2
• 206010006451 bronchitis Diseases 0.000 claims description 2
• 208000003167 cholangitis Diseases 0.000 claims description 2
• 201000001352 cholecystitis Diseases 0.000 claims description 2
• 208000023819 chronic asthma Diseases 0.000 claims description 2
• 208000007451 chronic bronchitis Diseases 0.000 claims description 2
• 208000017760 chronic graft versus host disease Diseases 0.000 claims description 2
• 208000027157 chronic rhinosinusitis Diseases 0.000 claims description 2
• 208000008609 collagenous colitis Diseases 0.000 claims description 2
• 238000012258 culturing Methods 0.000 claims description 2
• 201000003146 cystitis Diseases 0.000 claims description 2
• 239000003085 diluting agent Substances 0.000 claims description 2
• 201000001564 eosinophilic gastroenteritis Diseases 0.000 claims description 2
• 238000004519 manufacturing process Methods 0.000 claims description 2
• 208000008275 microscopic colitis Diseases 0.000 claims description 2
• 230000035772 mutation Effects 0.000 claims description 2
• 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
• 238000002271 resection Methods 0.000 claims description 2
• 238000000338 in vitro Methods 0.000 claims 2
• 239000000427 antigen Substances 0.000 claims 1
• 102000036639 antigens Human genes 0.000 claims 1
• 108091007433 antigens Proteins 0.000 claims 1
• 201000010099 disease Diseases 0.000 claims 1
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 4
• 238000003556 assay Methods 0.000 description 2
• 210000003071 memory t lymphocyte Anatomy 0.000 description 2
• 238000000159 protein binding assay Methods 0.000 description 2
• 241000282567 Macaca fascicularis Species 0.000 description 1
• 230000000295 complement effect Effects 0.000 description 1
• 208000037902 enteropathy Diseases 0.000 description 1
• 239000012634 fragment Substances 0.000 description 1
• 238000009396 hybridization Methods 0.000 description 1
• 238000001727 in vivo Methods 0.000 description 1
• 208000028774 intestinal disease Diseases 0.000 description 1
• 102000040430 polynucleotide Human genes 0.000 description 1
• 108091033319 polynucleotide Proteins 0.000 description 1
• 239000002157 polynucleotide Substances 0.000 description 1
• 239000000523 sample Substances 0.000 description 1
• 229920006395 saturated elastomer Polymers 0.000 description 1
• 238000012163 sequencing technique Methods 0.000 description 1
• 210000002966 serum Anatomy 0.000 description 1